Literature DB >> 23417373

Seronegative lyme neuroborreliosis in a patient using rituximab.

Willemijn Alexandra van Dop1, Marie-José Kersten, Bob de Wever, Joppe Willem Hovius.   

Abstract

A 66-year-old woman presented with severe shooting pains throughout her back and legs, followed by progressive deafness, weight loss and headache. She had a history of marginal zone B-cell lymphoma stage IV-B, for which she was successfully treated with immunochemotherapy and rituximab maintenance therapy. A relapse was suspected, but chemotherapy was not administered, since, despite elaborate investigations, malignancy could not be proven. Because of a history of tick bites she was tested for antibodies against Borrelia burgdorferi in serum and cerebrospinal fluid (CSF), which were negative. However, a B burgdorferi PCR on CSF came back positive. The patient was treated for seronegative Lyme neuroborreliosis with ceftriaxone intravenously and dramatically improved. This case presentation demonstrates that, in immunocompromised patients, it is important not to solely rely on antibody testing and to use additional diagnostic tests to avoid missing or delaying the diagnosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23417373      PMCID: PMC3604215          DOI: 10.1136/bcr-2012-007627

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

Review 1.  Lyme disease.

Authors:  A C Steere
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

Review 2.  Tired of Lyme borreliosis. Lyme borreliosis in the Netherlands.

Authors:  J Coumou; T van der Poll; P Speelman; J W R Hovius
Journal:  Neth J Med       Date:  2011-03       Impact factor: 1.422

3.  Incidence of Lyme borreliosis in the Würzburg region of Germany.

Authors:  H I Huppertz; M Böhme; S M Standaert; H Karch; S A Plotkin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-10       Impact factor: 3.267

4.  Measurement of antibodies to the Borrelia burgdorferi flagellum improves serodiagnosis in Lyme disease.

Authors:  K Hansen; P Hindersson; N S Pedersen
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

5.  Seronegative Lyme neuroborreliosis in a patient on treatment for chronic lymphatic leukemia.

Authors:  T Harrer; W Geissdörfer; C Schoerner; E Lang; G Helm
Journal:  Infection       Date:  2007-04       Impact factor: 3.553

6.  Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment.

Authors:  A Casabianca; M Marchetti; F Zallio; E Feyles; E Concialdi; E Ferroglio; A Biglino
Journal:  Infection       Date:  2011-05-03       Impact factor: 3.553

7.  EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis.

Authors:  A Mygland; U Ljøstad; V Fingerle; T Rupprecht; E Schmutzhard; I Steiner
Journal:  Eur J Neurol       Date:  2009-11-23       Impact factor: 6.089

8.  Clinical usefulness of intrathecal antibody testing in acute Lyme neuroborreliosis.

Authors:  U Ljøstad; T Skarpaas; A Mygland
Journal:  Eur J Neurol       Date:  2007-08       Impact factor: 6.089

9.  Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients.

Authors:  F Blanc; B Jaulhac; M Fleury; J de Seze; S J de Martino; V Remy; G Blaison; Y Hansmann; D Christmann; C Tranchant
Journal:  Neurology       Date:  2007-09-04       Impact factor: 9.910

10.  An epidemiologic study of Lyme disease in southern Sweden.

Authors:  J Berglund; R Eitrem; K Ornstein; A Lindberg; A Ringér; H Elmrud; M Carlsson; A Runehagen; C Svanborg; R Norrby
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  5 in total

1.  Lyme neuroborreliosis in a patient treated with TNF-alpha inhibitor.

Authors:  Maja Ivartnik Merkac; Janez Tomazic; Franc Strle
Journal:  Infection       Date:  2015-04-29       Impact factor: 3.553

Review 2.  Laboratory Diagnosis of Lyme Borreliosis.

Authors:  John A Branda; Allen C Steere
Journal:  Clin Microbiol Rev       Date:  2021-01-27       Impact factor: 26.132

3.  Erythema Migrans: Course and Outcome in Patients Treated With Rituximab.

Authors:  Vera Maraspin; Petra Bogovič; Tereza Rojko; Eva Ružić-Sabljić; Franc Strle
Journal:  Open Forum Infect Dis       Date:  2019-06-19       Impact factor: 3.835

4.  Neuroborreliosis with Unusual Presentation: A Case Report.

Authors:  Salman Khan; Gurjaspreet K Bhattal; Nikhil H Shah; Jorge Lascano; Apurwa Karki
Journal:  Cureus       Date:  2019-09-25

5.  Case report: persistently seronegative neuroborreliosis in an immunocompromised patient.

Authors:  A Wagemakers; M C Visser; B de Wever; J W Hovius; N W C J van de Donk; E J Hendriks; L Peferoen; F F Muller; C W Ang
Journal:  BMC Infect Dis       Date:  2018-08-02       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.